<DOC>
	<DOCNO>NCT00028522</DOCNO>
	<brief_summary>This phase I trial study side effect best dose R ( + ) XK469 treat patient advanced neuroblastoma . Drugs use chemotherapy work different way stop cancer cell divide stop grow die .</brief_summary>
	<brief_title>R ( + ) XK469 Treating Patients With Advanced Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose , recommend phase II dose , dose-limiting toxicity R ( + ) XK469 two different dose schedule patient advance neuroblastoma . II . Determine safety drug patient . III . Determine tolerance drug patient . IV . Determine pharmacokinetics pharmacodynamics drug metabolites patient . V. Determine , preliminarily , antineoplastic activity drug patient . OUTLINE : This dose-escalation study . SCHEDULE A : Patients receive R ( + ) XK469 intravenously ( IV ) 30 minute day 1 , 3 , 5 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos R ( + ) XK469 recommend phase II dose maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient accrue treat recommended phase II dose ( maximum 20 patient treat dose ) . SCHEDULE B : Once recommend phase II dose determine schedule A , additional patient accrue receive escalating dos R ( + ) XK469 IV 30-60 minute day 1 , begin reduce dose . Courses repeat every 3 week absence disease progression unacceptable toxicity . Dose escalation continue Schedule A .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>Histologically confirm highrisk neuroblastoma relapse refractory standard therapy No active brain metastasis Previously treat brain metastasis allow requirement corticosteroid anticonvulsant Performance status Karnofsky performance status 70100 % Lansky score â‰¥ 70 pediatric patient More 3 month WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin normal ( unless due document Gilbert 's syndrome ) Creatinine le 1.5 time upper limit normal No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent uncontrolled illness would preclude study participation No ongoing active infection No psychiatric illness social situation would preclude study participation No prior allergic reaction compound similar chemical biological composition study drug ( e.g. , flurbiprofen ibuprofen ) No HIVpositive patient No concurrent biologic agent At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) No concurrent chemotherapy See Disease Characteristics At least 4 week since prior radiotherapy No concurrent palliative radiotherapy See Disease Characteristics Recovered prior therapy No concurrent investigational agent No concurrent commercial agent therapy direct malignancy No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>